查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2058149

神經內分泌腫瘤（NETs）：新興療法、未滿足的需求和TPP洞察報告，2026年

Neuroendocrine Tumors (NETs) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到2035年，西班牙淨市場規模將從約 4.5億美元成長到 8.5億美元。
  • 市場成長受以下因素支撐：
  • 標靶治療和胜肽受體放射性核素治療（PRRT）的廣泛應用
  • 改善診斷技術和長期疾病監測
  • 市場規模的擴大是由治療週期延長和個人化癌症治療方法所推動的。
  • 未來的成長取決於新型標靶治療和放射性配體療法的廣泛應用。

神經內分泌腫瘤（NETs）的新治療方法及對TPP的深入研究

Thelansis 發布的《神經內分泌腫瘤（NET）：新興療法、未滿足的需求和 TPP 洞察報告，2026》全面分析了該適應症中的關鍵新興治療方法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況（TPP）、試驗設計和關鍵意見領袖（KOL）的見解。

神經內分泌腫瘤（NETs）概述

神經內分泌腫瘤（NETs）是一組高度異質性的腫瘤，起源於瀰漫性神經內分泌系統的分泌細胞，主要發生於胃腸道、胰管系統和肺部。它們以激素分泌活性多樣和生長抑制素受體過度表達為特徵。根據Ki-67生長指數，分化良好的NETs分為G1至G3級，而分化不良的神經內分泌癌則是另一組侵襲性較強的疾病。功能性NETs可引起荷爾蒙症候群，例如類癌症候群、胰島素瘤和胃泌素瘤，而非功能性NETs則常為偶然發現或表現為腫瘤壓迫症狀。診斷包括整合特定荷爾蒙檢測、DOTATATE PET-CT（在病灶檢測和分期方面表現出色）以及新型的基於mRNA的血液檢測，例如NETest。由於嗜鉻粒蛋白A特異性低、質子幫浦阻斷劑使用時常出現假陽性結果以及作為監測工具的效用有限，其重要性降低。手術切除仍是根治性治療的基礎。Octreotide和Lanreotide是生長抑制素類似物，具有抑制腫瘤生長和抑制腫瘤分泌的作用。基於NETTER-2試驗的資料，鎦-177多肽現已確立為進行性期、重度生長抑素受體陽性的2級和3級生長抑制素內分泌腫瘤（GEP-NETs）的一線標準治療方案，這標誌著與傳統晚期治療方案的根本性轉變。Everolimus和Sunitinib異性作用於胰臟神經內分泌腫瘤（NETs），而telotristat ethyl可抑制難治性類癌症候群相關的腹瀉。預後取決於惡性程度和病變範圍，但多學科管理和以患者為中心的症狀控制對於最佳化治療效果非常重要。

主要亮點

  • 根據預測，德國神經內分泌腫瘤新發病例數將從2025年的約 2,102 例增加到2035年的2,272 例。
  • 診斷影像技術的進步和基於生物標記的診斷方法的廣泛應用，提高了疾病的檢出率。
  • 神經內分泌腫瘤是一組異質性腫瘤，有不同的臨床表現和預後。
  • 治療選擇不斷增加，包括生長抑制素類似物、標靶治療和胜肽受體放射性核素治療（PRRT）。
  • 公眾意識的提高和早期診斷的普及改善了患者的治療效果。

透過對醫生和關鍵意見領袖（KOL）的調查所獲得的見解：

  • 透過對關鍵意見領袖（KOL）的訪談，獲得了更深入的見解，進一步豐富了研究成果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 主要企業
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等
  • 未滿足的需求和機會
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

主要企業

  • Orano Med LLC
  • ITM Solucin GmbH
  • Clarity Pharmaceuticals Ltd.
  • Crinetics Pharmaceuticals Inc.
  • TaiRx, Inc.
  • Advanced Accelerator Applications
  • Novartis Pharmaceuticals
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Boehringer Ingelheim
  • Perspective Therapeutics
  • Harbour BioMed（Guangzhou）Co. Ltd.
  • Exelixis
  • Hutchmed
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Chimeric Therapeutics
  • BioXcel Therapeutics Inc.
  • Teclison Ltd.
  • Circle Pharma
  • SAPU NANO（US）LLC
  • EpicentRx, Inc.
  • Novelty Nobility, Inc.
  • Arbele Pty Ltd.
  • Hoffmann-La Roche

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法 - 概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業屬性
  • 產品定位

第4章 一級市場調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章 未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與償付環境

第7章 附錄

簡介目錄

Neuroendocrine Tumors (NETs) Emerging Therapy and TPP Insights

Thelansis's "Neuroendocrine Tumors (NETs) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neuroendocrine Tumors (NETs) Overview

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms arising from secretory cells of the diffuse neuroendocrine system, occurring most commonly in the gastroenteropancreatic tract and lungs, characterised by variable hormonal secretory activity and somatostatin receptor overexpression. Well-differentiated NETs are graded G1 through G3 by Ki-67 proliferative index, while poorly differentiated neuroendocrine carcinomas represent a distinct aggressive entity. Functioning tumors produce hormonal syndromes including carcinoid syndrome, insulinoma, and gastrinoma, while non-functioning tumors present incidentally or with mass-effect symptoms. Diagnosis integrates specific hormonal assays, DOTATATE PET-CT for superior lesion detection and staging, and emerging mRNA-based blood assays including NETest; chromogranin A is increasingly de-emphasised given poor specificity, frequent false positivity with proton pump inhibitor use, and limited monitoring utility. Surgical resection remains the cornerstone of curative intent. Somatostatin analogues octreotide and lanreotide provide antiproliferative and antisecretory benefits. Lutetium-177 DOTATATE, supported by NETTER-2 trial data, is now established as first-line standard of care for advanced, high-burden somatostatin receptor-positive Grade 2 and Grade 3 GEP-NETs, representing a fundamental repositioning from later-line therapy. Everolimus and sunitinib address pancreatic NETs specifically, while telotristat ethyl controls refractory carcinoid syndrome diarrhoea. Prognosis varies with grade and disease extent; multidisciplinary management and patient-centred symptom control are integral to optimising outcomes.

Key Highlights

  • In Germany, incident neuroendocrine tumor cases are projected to increase from approximately 2,102 in 2025 to 2,272 by 2035.
  • Improved imaging and biomarker-based diagnostics are contributing to increased disease detection.
  • NETs represent a heterogeneous group of tumors with varying clinical behavior and prognosis.
  • Somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy (PRRT) continue to expand treatment options.
  • Rising awareness and earlier diagnosis are supporting improved patient outcomes.

Market Overview

  • The Spain NET market is projected to grow from approximately $450 MN to $850 MN by 2035.
  • Market growth is supported by:
  • Increasing adoption of targeted therapies and PRRT
  • Improved diagnosis and long-term disease monitoring
  • Market value growth is driven by extended treatment duration and personalized oncology approaches.
  • Future growth will depend on novel targeted therapies and expanded use of radioligand treatments.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Orano Med LLC
  • ITM Solucin GmbH
  • Clarity Pharmaceuticals Ltd.
  • Crinetics Pharmaceuticals Inc.
  • TaiRx, Inc.
  • Advanced Accelerator Applications
  • Novartis Pharmaceuticals
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Boehringer Ingelheim
  • Perspective Therapeutics
  • Harbour BioMed (Guangzhou) Co. Ltd.
  • Exelixis
  • Hutchmed
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Chimeric Therapeutics
  • BioXcel Therapeutics Inc.
  • Teclison Ltd.
  • Circle Pharma
  • SAPU NANO (US) LLC
  • EpicentRx, Inc.
  • Novelty Nobility, Inc.
  • Arbele Pty Ltd.
  • Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)